Epstein-Barr Virus: Biology and Clinical Disease

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2022 Sep 16

PMID 36113467

Authors

Blossom Damania

Shannon C Kenney

Nancy Raab-Traub

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV) is a ubiquitous, oncogenic virus that is associated with a number of different human malignancies as well as autoimmune disorders. The expression of EBV viral proteins and non-coding RNAs contribute to EBV-mediated disease pathologies. The virus establishes life-long latency in the human host and is adept at evading host innate and adaptive immune responses. In this review, we discuss the life cycle of EBV, the various functions of EBV-encoded proteins and RNAs, the ability of the virus to activate and evade immune responses, as well as the neoplastic and autoimmune diseases that are associated with EBV infection in the human population.

Citing Articles

Anti-Epstein-Barr Virus Activities of Flavones and Flavonols with Effects on Virus-Related Cancers.

Hassan S Molecules. 2025; 30(5).

PMID: 40076282 PMC: 11902172. DOI: 10.3390/molecules30051058.

Viral contamination in cell culture: analyzing the impact of Epstein Barr virus and Ovine Herpesvirus 2.

Bastawecy I, Abdelmonem M, Afify A, Saad N, Shirosaki Y, Abdullah C Front Microbiol. 2025; 16:1442321.

PMID: 40071201 PMC: 11893573. DOI: 10.3389/fmicb.2025.1442321.

Antivirotics based on defective interfering particles: emerging concepts and challenges.

Maryanchik S, Borovikova S, Ivanova A, Trofimov V, Bagrova O, Frolova A Front Cell Infect Microbiol. 2025; 15:1436026.

PMID: 40066067 PMC: 11891348. DOI: 10.3389/fcimb.2025.1436026.

Helicobacter pylori, microbiota and gastric cancer - principles of microorganism-driven carcinogenesis.

Wizenty J, Sigal M Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 40011753 DOI: 10.1038/s41575-025-01042-2.

REST Is Restless in Neuronal and Non-Neuronal Virus Infections: An In Silico Analysis-Based Perspective.

Pillai V, Ravindran S, Krishna G, Abhinand C, Nelson-Sathi S, Veettil M Viruses. 2025; 17(2).

PMID: 40006989 PMC: 11860772. DOI: 10.3390/v17020234.

References

Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J . EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol. 2010; 185(11):6439-47. DOI: 10.4049/jimmunol.0903459. View

Styles C, Bazot Q, Parker G, White R, Paschos K, Allday M . EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency. PLoS Biol. 2017; 15(8):e2001992. PMC: 5542390. DOI: 10.1371/journal.pbio.2001992. View

Miller W, Cheshire J, Raab-Traub N . Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol. 1998; 18(5):2835-44. PMC: 110662. DOI: 10.1128/MCB.18.5.2835. View

Davila Saldana B, John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S . High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2021; 6(2):452-459. PMC: 8791566. DOI: 10.1182/bloodadvances.2021005291. View

Kalchschmidt J, Bashford-Rogers R, Paschos K, Gillman A, Styles C, Kellam P . Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med. 2016; 213(6):921-8. PMC: 4886369. DOI: 10.1084/jem.20160120. View

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

Gilligan K, Rajadurai P, Lin J, Busson P, Abdel-Hamid M, Prasad U . Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol. 1991; 65(11):6252-9. PMC: 250325. DOI: 10.1128/JVI.65.11.6252-6259.1991. View

Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca K, Thorley-Lawson D . A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog. 2014; 10(5):e1004170. PMC: 4038605. DOI: 10.1371/journal.ppat.1004170. View

Shah K, Stewart S, Wei W, Woodman C, ONeil J, Dawson C . The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene. 2009; 28(44):3903-14. PMC: 2774296. DOI: 10.1038/onc.2009.249. View

10.

Kenney S, Mertz J . Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol. 2014; 26:60-8. PMC: 4048781. DOI: 10.1016/j.semcancer.2014.01.002. View

11.

Van Sciver N, Ohashi M, Pauly N, Bristol J, Nelson S, Johannsen E . Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells. PLoS Pathog. 2021; 17(8):e1009783. PMC: 8360610. DOI: 10.1371/journal.ppat.1009783. View

12.

Lunemann J, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R . EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008; 205(8):1763-73. PMC: 2525578. DOI: 10.1084/jem.20072397. View

13.

Zhang H, Li Y, Wang H, Zhang A, Chen M, Fang Z . Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Nat Microbiol. 2018; 3(2):1-8. DOI: 10.1038/s41564-017-0080-8. View

14.

Swaminathan S, Tomkinson B, Kieff E . Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A. 1991; 88(4):1546-50. PMC: 51056. DOI: 10.1073/pnas.88.4.1546. View

15.

Wu T, Mann R, CHARACHE P, Hayward S, Staal S, Lambe B . Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990; 46(5):801-4. DOI: 10.1002/ijc.2910460509. View

16.

Aubry V, Mure F, Mariame B, Deschamps T, Wyrwicz L, Manet E . Epstein-Barr virus late gene transcription depends on the assembly of a virus-specific preinitiation complex. J Virol. 2014; 88(21):12825-38. PMC: 4248913. DOI: 10.1128/JVI.02139-14. View

17.

Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W . The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000; 19(12):3080-9. PMC: 203345. DOI: 10.1093/emboj/19.12.3080. View

18.

Li Z, Tsai M, Shumilov A, Baccianti F, Tsao S, Poirey R . Epstein-Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production. Nat Microbiol. 2019; 4(12):2475-2486. DOI: 10.1038/s41564-019-0546-y. View

19.

Balfour Jr H, Sifakis F, Sliman J, Knight J, Schmeling D, Thomas W . Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013; 208(8):1286-93. DOI: 10.1093/infdis/jit321. View

20.

Ramiro A, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M . AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004; 118(4):431-8. DOI: 10.1016/j.cell.2004.08.006. View